Clinical Trial Update: RBN-2397 in Combination With Pembrolizumab in Patients With SCCL [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial investigating RBN-2397 in combination with pembrolizumab in advanced squamous non-small cell lung carcinoma is in Phase 1/2 with status not dis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Non-small Cell Lung Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• RBN-2397 (RBN-2397)

Snippet

Sponsor: Ribon Therapeutics, Inc. | Conditions: Advanced Squamous Non-Small Cell Lung Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN